Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could spot dangerous pancreatic cysts with greater accuracy

NCT ID NCT07463872

Diagnosis Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing an artificial intelligence model called Cyst-AI that uses endoscopic ultrasound images and patient data to help doctors tell apart different types of pancreatic cysts. The goal is to improve diagnosis and guide treatment decisions. Researchers plan to enroll 500 adults with pancreatic cysts to see how well the AI performs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cyst-AI model (diagnostic test)
What this could lead to
If successful, this AI tool could help doctors more accurately diagnose pancreatic cysts and decide on the best treatment, potentially reducing unnecessary surgeries.
What could go wrong
This is an early-stage study with 500 participants, and the AI model may not perform as well in real-world settings or with different patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The cohort will be selected from several hospitals in China, including Tongji Hospital, Tongji Medical College, HUST.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients whose EUS results indicates pancreatic cystic or cystoid lesions; * Mucinous lesions: including mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN); * Non-mucinous lesions: including pancreatic pseudocyst, serous cystic neoplasm (SCN), cystic neuroendocrine tumor (cNET). Exclusion criteria: * Patients whose age is less than 18 years old; * Patients who have undergone pancreatic surgery before the EUS examination; * Patients who have received chemotherapy and radiotherapy for pancreatic tumors before the EUS examination; * Pathological results indicate that pancreatic lesions are metastatic lesions from other sites; * Patients whose EUS images or reports are missing; * EUS image quality does not meet the requirements for review, such as blurry imaging or containing artifacts, biopsy needles, measuring scales, or other additional annotations that are not part of the original EUS image; * Patients whose final diagnosis is unclear.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intraductal papillary mucinous neoplasm of pancreas are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cystadenoma, Serous cystic tumor of the pancreas neuroendocrine neoplasm Pancreatic Intraductal Neoplasms pancreatic intraductal papillary-mucinous neoplasm pancreatic mucinous cystadenoma pancreatic mucinous-cystic neoplasm Pancreatic Pseudocyst pancreatic serous cystic neoplasm serous cystadenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intraductal papillary mucinous neoplasm of pancreas Mucinous cystadenoma of pancreas Neuroendocrine tumors, net Pancreatic cystic lesion Pseudocyst pancreas Serous cystadenoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430030, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.